博騰股份(300363.SZ):控股子公司擬啟動製劑工廠一期建設項目
格隆匯 9 月 11日丨博騰股份(300363.SZ)公佈,公司於2020年9月11日召開第四屆董事會第二十次臨時會議,審議通過《關於製劑工廠一期建設項目的議案》。
經公司第四屆董事會第七次臨時會議審議通過,2019年8月29日公司控股子公司重慶博騰藥業有限公司(“博騰藥業”)註冊成立,公司正式啟動製劑CDMO平台建設,承接藥物開發、臨牀供應及上市階段所需的製劑CDMO業務。製劑CDMO業務開展的前提是具備製劑實驗室及GMP產能,截至目前,博騰藥業的重慶研發實驗室、上海研發實驗室已分別按計劃積極推進,為支持公司製劑CDMO業務規劃和發展,具備製劑GMP生產及放行能力,博騰藥業擬在重慶兩江新區投資27847.07萬元啟動製劑工廠一期建設項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.